http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 08:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Press+Releases/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce its financial results for the first quarter ended March 31, 2026, and to provide a corporate update on recent activities and upcoming milestones.</p> <p align="justify">The Company’s full set of unaudited condensed interim consolidated financial statements for the three months ended March 31, 2026, and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at <a target="_blank" href="https://www.globenewswire.com/Tracker?data=JU0ulU0FfkHBsxGyOqXXrFrL1aQjOhSP0j6D-MacSBHaBogi2UqlHGH3YT231LzZpkp8MUWK9PSLNM5QTbSjwSAhiFpFXHrixjBiNhEaSSyYL3IPWIEsA-sXzq87NaPcAe5PjqT-BzZ49Pw03c67mjq6LtpsAgtsfhdXAQ4VDG50nz_njRZa4tsE6Zv9dk4G6rvoxLqsDeiEieiLDkBww_3MfuvaVSM4hbyHfJw5c4xmewti45WJbz30P9xw5bYA0J6VahaAcX2R1u0PMTFTIg==" rel="nofollow" http://www.streetinsider.com/Globe+Newswire/NurExone+Announces+First+Quarter+2026+Financial+Results+and+Provides+Corporate+Update/26579625.html Mon, 01 Jun 2026 08:02:00 -0400 A.28851260 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 O.13812225 http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice of Patent Grant for a patent application covering ExoPTEN, the Company’s lead therapeutic candidate.</p> <p align="justify">The patent application covers key aspects of ExoPTEN, including the use of exosomes as a natural drug delivery system to carry PTEN-targeted therapeutic cargo for the treatment of nerve injury.</p> <p align="justify">Dr. Lior Shaltiel, CEO http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html Tue, 19 May 2026 16:04:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice of Patent Grant for a patent application covering ExoPTEN, the Company’s lead therapeutic candidate.</p> <p align="justify">The patent application covers key aspects of ExoPTEN, including the use of exosomes as a natural drug delivery system to carry PTEN-targeted therapeutic cargo for the treatment of nerve injury.</p> <p align="justify">Dr. Lior Shaltiel, CEO http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html Tue, 19 May 2026 16:04:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice of Patent Grant for a patent application covering ExoPTEN, the Company’s lead therapeutic candidate.</p> <p align="justify">The patent application covers key aspects of ExoPTEN, including the use of exosomes as a natural drug delivery system to carry PTEN-targeted therapeutic cargo for the treatment of nerve injury.</p> <p align="justify">Dr. Lior Shaltiel, CEO http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html Tue, 19 May 2026 16:04:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice of Patent Grant for a patent application covering ExoPTEN, the Company’s lead therapeutic candidate.</p> <p align="justify">The patent application covers key aspects of ExoPTEN, including the use of exosomes as a natural drug delivery system to carry PTEN-targeted therapeutic cargo for the treatment of nerve injury.</p> <p align="justify">Dr. Lior Shaltiel, CEO http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html Tue, 19 May 2026 16:04:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice of Patent Grant for a patent application covering ExoPTEN, the Company’s lead therapeutic candidate.</p> <p align="justify">The patent application covers key aspects of ExoPTEN, including the use of exosomes as a natural drug delivery system to carry PTEN-targeted therapeutic cargo for the treatment of nerve injury.</p> <p align="justify">Dr. Lior Shaltiel, CEO http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html Tue, 19 May 2026 16:04:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice of Patent Grant for a patent application covering ExoPTEN, the Company’s lead therapeutic candidate.</p> <p align="justify">The patent application covers key aspects of ExoPTEN, including the use of exosomes as a natural drug delivery system to carry PTEN-targeted therapeutic cargo for the treatment of nerve injury.</p> <p align="justify">Dr. Lior Shaltiel, CEO http://www.streetinsider.com/Press+Releases/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html Tue, 19 May 2026 16:04:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice of Patent Grant for a patent application covering ExoPTEN, the Company’s lead therapeutic candidate.</p> <p align="justify">The patent application covers key aspects of ExoPTEN, including the use of exosomes as a natural drug delivery system to carry PTEN-targeted therapeutic cargo for the treatment of nerve injury.</p> <p align="justify">Dr. Lior Shaltiel, CEO http://www.streetinsider.com/Globe+Newswire/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html Tue, 19 May 2026 16:04:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice of Patent Grant for a patent application covering ExoPTEN, the Company’s lead therapeutic candidate.</p> <p align="justify">The patent application covers key aspects of ExoPTEN, including the use of exosomes as a natural drug delivery system to carry PTEN-targeted therapeutic cargo for the treatment of nerve injury.</p> <p align="justify">Dr. Lior Shaltiel, CEO http://www.streetinsider.com/Globe+Newswire/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html Tue, 19 May 2026 16:04:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008 http://www.streetinsider.com/Globe+Newswire/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html <p align="justify">TORONTO, Ontario and HAIFA, Israel, May 19, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, today announced that the Korean Ministry of Intellectual Property (“MOIP”) has issued a Notice of Patent Grant for a patent application covering ExoPTEN, the Company’s lead therapeutic candidate.</p> <p align="justify">The patent application covers key aspects of ExoPTEN, including the use of exosomes as a natural drug delivery system to carry PTEN-targeted therapeutic cargo for the treatment of nerve injury.</p> <p align="justify">Dr. Lior Shaltiel, CEO http://www.streetinsider.com/Globe+Newswire/NurExone+Receives+Notice+of+Patent+Grant+in+South+Korea+Covering+ExoPTEN+Technology/26520953.html Tue, 19 May 2026 16:04:00 -0400 A.36078215 J90 NRX NRXBF O.02555813 O.13737008